EBOS Group Limited (EBO.AX), which markets and distributes healthcare, medical, pharmaceutical and animal care products in Australia, on Thursday outlined its strategy, growth plans and capital priorities at an Investor Day in Sydney.
Over the next three years, the company expects capital expenditure to decline from fiscal 2027, supporting earnings per share growth from fiscal 2028 onwards, along with mid-single-digit organic underlying EBITDA growth.
The company said it has redeployed around $2 billion over the past five years into higher-growth businesses, including medical technology and animal care, as it continues to shift its portfolio toward higher-return segments.
It also reaffirmed a dividend payout of 60%-80% of underlying net profit after tax.
The group noted that capital expenditure is expected to peak in fiscal 2026 before easing from fiscal 2027.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.